**Definitive Radiotherapy Concurrent with Carboplatin in the Treatment of Locally Advanced Head and Neck Cancers in Patients Ineligible for Cisplatin**

Alaa Maria and Amro Ghannam

Clinical Oncology Department, Faculty of Medicine, Tanta University, Egypt.

[alaamaria1@hotmail.com](mailto:alaamaria1@hotmail.com)

**Abstract: Purpose:** The objective of this study is to analyze the clinical outcomes and practicability of concurrent carboplatin plus radiation therapy (RT) in patients diagnosed as locally progressive squamous cell carcinoma of the head and neck (LA-SCCHN) that are ineligible for cisplatin treatment. **Patients and methods:** Thirty-one patients with histologically confirmed LA-SCCHN were eligible. All patients received carboplatin concurrent with conventionally fractionated RT. **Results:** The median age of our patients was 65 (range: 40–75) years with male predominance. Laryngeal cancer constitutes 51.6% with 61.3% had performance status (PS) 2 and 71% had stage IV disease. Carboplatin administered tri-weekly in 22 (71%) patients. The main causes for choosing carboplatin were advanced age and PS of 2 (61.3%). Twenty-five (80.6%) patients received the pre-specified dose of carboplatin. Twenty-seven (87.1%) patients received RT to 70 Gy a total dose. The median duration of RT was 54 days (range, 47–65). Complete response was observed in 32.3% of patients. The commonest grade 3/4 toxicities were oral mucositis and vomiting (22.6%), nausea (19.4%), dysphagia (12.9%), and anemia (19.4%). At the end of the study, 21 (67.7%) patients were alive with a follow-up period ranged from 9-44 (median 25) months. The median overall survival (OS) and progression-free survival (PFS) were not reached with 2-year OS & PFS rates were 74.7% and 54.8% respectively. **Conclusion:** Concurrent radiation therapy plus carboplatin is feasible and is a treatment option for LA-SCCHN patients who are ineligible for cisplatin treatment.

**[**Alaa Maria and Amro Ghannam. **Definitive Radiotherapy Concurrent with Carboplatin in the Treatment of Locally Advanced Head and Neck Cancers in Patients Ineligible for Cisplatin.** *Cancer Biology* 2018;8(4):146-151]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). <http://www.cancerbio.net>. 12. doi:[10.7537/marscbj080418.12](http://www.dx.doi.org/10.7537/marscbj080418.12).

**Key Words:** Locally advanced, head and neck cancer, squamous cell carcinoma, carboplatin

**1. Introduction**

Globally, cancers affecting head and neck account for more than 550,000 cases yearly worldwide [1]. The report of 2017 of the United States, statistics, concerning head and neck tumors, measured 63,030 new cases and the number of deaths reached 13,360 cases [2]. Nearly 95% of these cancers are squamous cell carcinomas (SCC) originating principally from the oropharynx, hypopharynx, larynx, and oral cavity [3].

The standard of care for organ preservation is definitive concurrent chemoradiotherapy (CRT) that is considered the merely possible treatment in surgically unresectable or unfit subjects with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) with stage III to IVb. The fractionation program is 70 Gy (2 Gy/fraction) over seven weeks, with concurrent high-dose cisplatin 100 mg/m2 on days 1, 22, and 43. This regimen was tested in the trials by the Intergroup [4] and the Radiation Therapy Oncology Group (RTOG) 91-11 [5], using cisplatin-based concurrent chemoradiotherapy.

A total of 233 subjects included in a retrospective work, 50% of the participating patients who received high-dose cisplatin-based CRT for treatment from head and neck tumor affected with acute renal injury in spite of caution in selection of patient, addition of mannitol to keep urinary flow, and liberal hydration [6]. Thus, patients who are disqualified for cisplatin therapy, for instance elderly patients, cardiac, renal, respiratory or neurogenic disordered, are often treated with radiation therapy alone as a definitive treatment.

Carboplatin is an analog of cisplatin second-generation, characterized by a lower incidence of neurotoxicity, gastrointestinal toxicity, and nephrotoxicity in contrast to cisplatin [7]. Carboplatin has been conventionally used as an alternative to cisplatin for treatment of head and neck cancers concurrently with radiation therapy, especially in patients who may be ineligible for cisplatin due to its toxicity. However, the efficacy and toxicity of concurrent carboplatin and radiation therapy are not clear for LA-SCCHN patients who are ineligible for treatment with cisplatin [8].

In the present investigation, we prospectively explored the clinical consequences, feasibility, and toxicity of concomitant carboplatin and radiation therapy in patients with LA-SCCHN who are unfit for treatment by cisplatin.

**2. Patients and methods**

This is a prospective study that was conducted at Clinical Oncology Department, Faculty of Medicine, Tanta University between August 2014 and August 2017. This study was approved by our faculty ethical committee with written informed consent was obtained from all included patients.

Patients with histologically confirmed locally or regionally advanced stage III or IV (Union for International Cancer Control Tumor, Node, Metastasis classification, 7th edition) [9] SCCHN without evidence of distant metastasis were eligible for this study.

**Eligibility criteria**

All patients aged between 16 and 75 years with pathologically proven SCC of the oral cavity, oropharynx, larynx or hypopharynx confirmed radiologically by computed tomography (CT) or magnetic resonance imaging (MRI) with no systemic metastasis. Ineligibility for cisplatin treatment due to of any of the following reasons: old age, renal impairment (creatinine clearance [CCr] less than 60 ml/min), neurologic impairment (peripheral neuropathy or hearing impairment), cardiac dysfunction (a history of myocardial infarction, unstable angina or chronic heart failure), or performance status (PS) of ≥2 according to the Eastern Cooperative Oncology Group (ECOG). Adequate hematologic picture, hepatic and renal function.

**Exclusion criteria**

Patients were excluded if they received prior chemotherapy and/or radiotherapy, had prior surgery, active infection, or had a second malignancy.

**Treatment**

Administration of induction chemotherapy (ICT) regimen as an IV infusion of carboplatin (area under the curve AUC, 5; day 1) and 5-fluorouracil (1000 mg/m2, continuous infusion days 1–4) repeated every 21 days for three cycles.

All patients received carboplatin concurrent with conventionally fractionated RT. Carboplatin was administered either tri-weekly [AUC, 5 on days 1, 22 and 43] or weekly (AUC, 2 on days 1, 8, 15, 22, 29, 36 and 43) according to the physicians’ discretion.

The regimen was discontinued if there was unacceptable toxicity, which renders further treatment detrimental to patients, delay of more than two weeks for blood counts to recover or for renal toxicity to improve to grade 2 or less, or at patient request.

**Radiotherapy**

For tumor localization, the extent of the primary tumor and the neck nodes were assessed by using a CT scan. The field arrangement was individualized. All cases were treated with three-dimensional conformal radiation therapy (3DCRT) with 6 MV linear accelerator. The gross tumor volume (GTV) was treated with 2 Gy per fraction, five days per week to a total dose of 70 Gy, 60 Gy to the high-risk clinical target volume (CTV) and 54 Gy to low-risk CTV. Selected patients with the resectable residual disease after definitive CRT had salvage surgery.

**Evaluation**

Pretreatment evaluations included; medical history and physical examination, laboratory tests, endoscopy, CT, MRI and [18F]-fluorodeoxyglucose positron-emission tomography/CT fusion imaging if indicated. Assessment of tumor response by CT or MRI 4–6 weeks after the completion of CRT or when clinical signs suggested progressive disease, according to the guidelines of the Response Evaluation Criteria in Solid Tumors, version 1.1 [10]. The World Health Organization (WHO) grading system [11] and the Radiation Therapy Oncology (RTOG) acute morbidity scoring criteria [12] are used to record the toxicities during the course of treatment.

**Follow-up**

The first follow-up visit was one month after finishing CRT. Evaluation for locoregional control, treatment toxicity and survival outcomes was done every two months for the first year, every 3–4 months for the second and third year and at 6 month intervals later.

**Statistical analysis**

The estimation of locoregional control (LRC) rate is the primary objective. The estimation of overall survival (OS), progression-free survival (PFS), and evaluation of adverse events in all included patients are the secondary objectives. Progression-free survival was defined as the time between treatment start and development of disease progression, relapse, or death from any cause. Overall survival was defined as the time interval between the date of diagnosis and the date of death or last follow-up.

Kaplan-Meier method was used for estimating the survival rates. All analyses were performed using SPSS software, version 21.0 and *p*-value <0.05 was considered statistically significant.

**3. Results**

**Patient characteristics**

Between August 2014 and August 2017, 31 patients with LA-SCCHN underwent definitive CRT with carboplatin. Table 1 shows the baseline characteristics of included patients. The median age of included patients was 65 (range: 40–75) years with 19 (61.3%) patients were older than 65 years of age with male predominance (67.7%). Laryngeal cancer constitutes 51.6% of all cases with 61.3% of all cases had ECOG-PS 2 and 71% of patients had stage IV disease. Carboplatin was administered every three weeks in 22 (71%) patients.

Table 2 shows the main causes of choosing carboplatin. If any of the five causes are present, the patient is considered to be unfit for the treatment with cisplatin. The common reasons for selecting carboplatin were old age and PS of 2 followed by renal impairment [10 patients were considered to have a renal impairment with median CCr of 53 ml/min], cardiac dysfunction and hearing impairment.

**Table (1): Patients and tumor characteristics**

|  |  |
| --- | --- |
| **Characteristics** | **No (%)** |
| **Age (years)**  Median  Range  Mean±SD  >65  ≤65 | 65  38-75  56.97±10.93  19 (61.3)  12 (38.7) |
| **Gender**  Male  Female | 21 (67.7)  10 (32.3) |
| **Smoking**  Yes  No | 17 (54.8)  14 (45.2) |
| **Site**  Larynx  Oral cavity  Oropharynx  Hypopharynx | 16 (51.6)  5 (16.1)  7 (22.6)  3 (9.7) |
| **Performance status**  0  1  2 | 2 (6.4)  10 (32.3)  19 (61.3) |
| **Tumor grade**  1  2  3 | 6 (19.4)  15 (48.4)  10 (32.2) |
| **T stage**  1  2  3  4 | 2 (6.4)  8 (25.8)  6 (19.4)  15 (48.4) |
| **N stage**  0  1  2  3 | 4 (12.9)  5 (16.1)  16 (51.6)  6 (19.4) |
| **Stage**  III  IVa  IVb | 9 (29)  16 (51.6)  6 (19.4) |
| **Creatinine clearance (ml/min)**  median (range) | 62 (37-117) |
| **Carboplatin administration**  Triweekly  weekly | 22 (71)  9 (29) |
| **Induction chemotherapy**  Yes  No | 25 (80.6)  6 (19.4) |
| **Resectability**  Yes  No | 19 (61.3)  12 (38.7) |

**Treatment compliance**

Twenty-five (80.6%) patients received the pre-specified dose of carboplatin. All patients received an optimal dose of radiation therapy, defined as 60 Gy or more. Twenty-seven (87.1%) patients received a total dose of 70 Gy. The median duration of RT was 54 days (range, 47–65). Treatment interruption was reported in 26 (83.9%) patients with 8 (range, 0-18) days median time of interruption and 4 (12.9%) patients discontinued their planned treatment after 60 Gy due to side effects. Seventy-one percent of patients received tri-weekly carboplatin plus RT. However, tri-weekly carboplatin was less tolerable than the weekly regimen.

**Table 2: Indication for carboplatin**

|  |  |
| --- | --- |
|  | No. (%) |
| Age over 65 years | 19 (61.3) |
| Performance status 2 | 19 (61.3) |
| Renal impairment | 10 (32.2) |
| Cardiac dysfunction | 4 (12.9) |
| Hearing impairment | 1 (3.2) |

**Clinical response**

Ten patients (32.3%) had complete response (CR) and a partial response (PR) was in 12 (38.7%) patients with 71.0% (22/31) total response rate (CR and PR). Disease stability was reported in 8 (25.8%) patients and only one patient (3.2%) developed progressive disease. Two subjects had rescue surgery for remaining neck disease three and four months after end of RT with postoperative neck edema was the major complication.

**Toxicity**

Table 3 shows the main toxicities observed during CRT. The main non-hematological toxicities reported was mainly related to the radiation effect on surface mucosa with the resultant grade III/IV mucositis & vomiting seen in 7 (22.6%) patients, nausea in 6 (19.4%) patients, and dysphagia in 4 (12.9%) patients. The other non-hematological toxicities were grade I and II and were managed properly.

Myelotoxicity was common, with grade I-II anemia, leukopenia, and thrombocytopenia seen in 61.2%, 80.6%, and 74.2%, of patients, respectively. Tri-weekly regimen showed higher rates of toxicities versus weekly regimen; however, it was non-significant. Three patients developed an infection, including two with pneumonia, and one with febrile neutropenia. However, the regimen was well tolerated with no treatment-related death was reported.

**Survival**

At the end of the study, 21 (67.7%) cases were still alive after a follow-up period ranged from 9-44 (median 25) months. As regards the survival outcome, the median OS was not reached. The mean OS was 34.6 (95%CI, 30-39.3) months with 74.7% 2-year OS rate. The median PFS was not reached. The mean PFS was 27.8 (95% CI, 22.1-33.4) months with 54.8% 2-year PFS rate. (Figures 1 & 2).

**Table (3): Toxicity of treatment**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Toxicity** | **Grade I/II No (%)** | | | **Grade III/IV No (%)** | | | | ***p*** |
| **Total** | **Triweekly** | **Weekly** | **Total** | **Triweekly** | **Weekly** | |
| **Hematological** |  |  |  |  |  |  |  | |
| Anemia | 19 (61.2) | 15 (78.9) | 4 (21.1) | 6 (19.4) | 4 (66.7) | 2 (33.3) | | 0.383 |
| Leukopenia | 25 (80.6) | 19 (76.0) | 6 (24.0) | 3 (9.7) | 2 (22.7) | 1 (33.3) | | 0.302 |
| Thrombocytopenia | 23 (74.2) | 18 (78.3) | 5 (21.7) | 5 (16.1) | 3 (60.0) | 2 (40.0) | | 0.229 |
| **Non-hematological** | | | | | | | | |
| Mucositis | 24 (77.4) | 18 (75.0) | 6 (25.0) | 7 (22.6) | 4 (57.1) | 3 (42.9) | | 0.360 |
| Anorexia | 29 (93.5) | 20 (69.0) | 9 (31.0) | 0 (0) | 0 (0) | 0 (0) | | 0.350 |
| Nausea | 23 (74.2) | 18 (78.3) | 5 (21.7) | 6 (19.4) | 3 (50.0) | 3 (50.0) | | 0.317 |
| Vomiting | 20 (64.5) | 14 (70.0) | 6 (30.0) | 7 (22.6) | 5 (71.4) | 2 (28.6) | | 0.980 |
| Dysphagia | 20 (64.5) | 15 (75.0) | 5 (25.0) | 4 (12.9) | 2 (50.0) | 2 (50.0) | | 0.603 |
| Diarrhea | 8 (25.8) | 5 (62.5) | 3 (37.5) | 0 (0) | 0 (0) | 0 (0) | | 0.540 |
| Neuropathy | 9 (29.0) | 7 (77.8) | 2 (22.2) | 0 (0) | 0 (0) | 0 (0) | | 0.593 |
| Renal impairment | 4 (12.9) | 3 (75.0) | 1 (25.0) | 0 (0) | 0 (0) | 0 (0) | | 0.849 |

|  |  |
| --- | --- |
| D:\ابحاث الترقية الجديدة\7 Carboplatin in H&N\OS.png | D:\ابحاث الترقية الجديدة\7 Carboplatin in H&N\PFS.png |
| Figure 1: Overall survival | Figure 2: Progression free survival |

**4. Discussion**

Concurrent radiation therapy with high dose cisplatin represents the definitive treatment for unresectable, surgically unfit LA-SCCHN [4, 13] with 40% CR and median OS of 19.1 months. Two phase III adjuvant trials confirmed that the therapy with cisplatin enhances loco-regional control and disease-free survival (DFS) in comparison to radiation alone with mixed results on OS [13, 14]. Bernier et al. [14] established that both 5-year PFS (47% vs 36%) and OS (53% vs 40%; HR=0.70; 95% CI 0.52–0.95) favored contemporary CRT above RT alone.

In addition to cisplatin, cetuximab (Cmab, an epidermal growth factor receptor monoclonal antibody), was used in combination with RT with significant improvement of the loco-regional control, PFS, and OS compared with radiation therapy alone. Regarding toxicity, concurrent Cmab and RT led to a higher grade III/IV skin toxicity versus RT alone (35.1 vs. 21.2%, *p*<0.05) [15, 16]. Other trial reported grade III/IV radiation dermatitis in more than 30% of patients [17, 18]. Severe skin reactions could lead to treatment interruption and dose reduction with a quality of life reduction. Currently, no recommendation supports the use of concurrent RT with Cmab as an alternative to RT alone in patients with cisplatin intolerance.

The mechanism of action of both carboplatin and cisplatin is similar. They both induce the same platinum-DNA adducts. Hongo et al. [19] demonstrated that carboplatin required 7.5 times longer incubation time and concentration of drug 10 times higher than cisplatin to make an equal degree of conformational change on plasmid DNA. Myelosuppression is recognized to be higher with carboplatin than cisplatin however induces low neurotoxicity, nausea with hyperemesis, and nephrotoxicity [20].

The antitumor effect of cisplatin is more powerful than carboplatin. It is not clear whether carboplatin has the same radio-sensitizing effect as cisplatin or not. In model, carboplatin could exchange cisplatin in some individuals who have not allowed to given cisplatin, particularly in individuals with baseline hearing impairment, inadequate renal function, and marginal performance status, or those who may have trouble accepting hydration with high fluid volume accompanied with higher doses of cisplatin such as patients with congestive heart failure or severe emphysema [21].

Although 71% of our patients had stage IV and 38.7% had unresectable tumors, about 32% achieved CR. These results suggest that concurrent carboplatin and radiation therapy achieved very good treatment outcomes. As regards the survival outcome in our study, the follow-up period ranged from 9-44 (median 25) months with the median OS and PFS were not reached. The mean OS was 34.6 months with 74.7% 2-year OS rate. The mean PFS was 27.8 months with 54.8% 2-year PFS rate.

In a prospective randomized clinical trial in individuals complained from locally advanced nasopharyngeal carcinoma (NPC), concurrent carboplatin (100 mg/m2) administered weekly during RT demonstrated better tolerability with comparable efficacy when compared with concurrent tri-weekly cisplatin (100 mg/m2) and RT [22]. The 3-year OS and DFS was 79% vs 78% and 61% vs 63% for the carboplatin and cisplatin regimens, respectively (*p*>0.05).

For LA-SCCHN other than NPC, a prospective randomized three-arm phase III trial [23] compared the 3-year survival rate with 70 Gy radiation therapy given alone, concurrent cisplatin (100 mg/m2 tri-weekly) plus RT, and concurrent carboplatin (AUC, 7 tri-weekly) plus RT. This trial reported that platinum-based containing therapy prolonged the 3-year survival significantly when matched with radiation therapy alone. Survival rate was 42% for carboplatin, 52% for cisplatin, and 17.5% for RT alone.

There is no precise agreement for being unfit for the cisplatin use. Therefore, in our study, we considered the patient ineligible for high dose cisplatin based on the known toxicity of cisplatin and on the exclusion or inclusion conditions used in the clinical trials using cisplatin for head and neck cancer. So, we enumerated five factors in the materials and methods section. Carboplatin has less nephrotoxicity, neurotoxicity, nausea and vomiting, no requirement for much hydration, compared with cisplatin. So, we think that carboplatin is safer than cisplatin for those who encounter our criteria.

Although all of our patients were considered unfit for cisplatin therapy, principally due to old age or poor performance status, they received an optimal dose of radiation therapy, defined as more than 60 Gy.

Regarding the toxicity of carboplatin; in a study by Jodrell et al. [24], there was a significant correlation among administered AUC dose of carboplatin and the probability of development of leukopenia and thrombocytopenia. Hence, we can avoid the myelotoxicity induced by high doses of carboplatin that can cause infection. Low dose weekly carboplatin plus RT may be less myelotoxic.

There was no grade III/IV neurotoxicities, nephrotoxicity. However, termination or dose reduction of carboplatin was obligatory owing to myelotoxicity in the patients of the current work as three patients had an infection and febrile neutropenia.

Tri-weekly carboplatin plus RT was not compared in clinical trials with weekly carboplatin plus RT. In the aforementioned randomized trial for locally advanced NPC, weekly carboplatin plus RT was as effective as RT plus tri-weekly cisplatin that caused grade III or IV leukopenia and thrombocytopenia in 10% and 8% of patients respectively [22]. For non-nasopharyngeal LA-HNSCC, Tri-weekly carboplatin plus RT caused grade III or IV leukopenia and thrombocytopenia in 18% and 27% of patients respectively [23]. These results suggest that the myelotoxicity of weekly carboplatin plus RT is lesser than that produced by tri-weekly carboplatin plus RT and may be considered as an alternative therapy in LA-SCCHN.

In the present work, high percentage of cases (71%) received tri-weekly carboplatin plus RT. However, tri-weekly carboplatin caused more myelotoxicity which subsequently leads to infection and neutropenic fever that can be explained by the older age of our patients. Therefore, weekly carboplatin plus radiation therapy is more favored in our hospital due to its mild myelotoxicity.

In conclusion, concurrent radiation therapy plus carboplatin is feasible and is a treatment option for LA-SCCHN patients who are ineligible for cisplatin treatment. Small number of patients and performance at a single oncology center were restrictions of the present study. So, our results should be confirmed with more prospective multi-institutional studies with a large number of patients.

**Conflict of Interest**

The authors declare no conflict of interest

**References**

# 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.

# 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.

# 3. Nagasaka M, Zaki M, Issa M, Kim H, Abrams J, Sukari A. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. [Laryngoscope.](https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Laryngoscope%2C+2017.+127(10)%3A+p.+2260-2264) 2017;127(10):2260-4.

4. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. [J Clin Oncol.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Journal+of+clinical+oncology%2C+2003.+21(1)%3A+p.+92-98.) 2003;21(1):92-8.

5. Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg. 2003;129(1):44-9.

6. Bhat ZY, Cadnapaphornchai P, Ginsburg K, Sivagnanam M, Chopra S, Treadway CK, et al. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study. PLoS One. 2015;10(11):e0142225.

7. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9(1):13-21.

8. Hamauchi S, Yokota T, Onozawa Y, Ogawa H, Onoe T, Kamijo T, et al. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Jpn J Clin Oncol. 2015;45(12):1116-21.

# 9. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.

10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.

11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14.

12. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6.

13. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-50.

14. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-52.

15. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-78.

16. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-8.

17. Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol. 2009;90(2):166-71.

# 18. Studer G, Brown M, Salgueiro EB, Schmückle H, Romancuk N, Winkler G, et al. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT. Int J Radiat Oncol Biol Phys. 2011;81(1):110-7.

19. Hongo A, Seki S, Akiyama K, Kudo T. A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. Int J Biochem. 1994;26(8):1009-16.

20. Zakotnik B, Smid L, Budihna M, Lesnicar H, Soba E, Furlan L, et al. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Phys. 1998;41(5):1121-7.

21. Marcial VA, Pajak TF. Radiation therapy alone or in combination with surgery in head and neck cancer. Cancer. 1985;55(9 Suppl):2259-65.

# 22. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer. 2007;43(9):1399-406.

23. Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol. 2004;21(2):95-107.

24. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520-8.